Docgo (DCGO) reported $322M in revenue for fiscal 2025, −47.7% year on year. That ranks #2446 by revenue among 2853 SEC filers and #243 in Healthcare. It posted a net loss of −$196M for the same year. Revenue has grown 27.9% a year on average since 2020 ($94.1M then). The fiscal 2025 balance sheet shows $217M in total assets, $51.0M in cash and $183,843 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $322M | −47.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$178M | −$207M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$196M | −$210M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $34.5M | −50.9% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.5M | +25.8% | FY20252025-12-31 |
| Total assetsAssets | $217M | −52.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $144M | −55.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $51.0M | −42.8% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $183,843 | +3,425.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $75.6M | −$14.8M | Open → |
| Q2 20262026-06-30 | $73.4M | −$15.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Docgo Inc.
- Ticker
- DCGO
- Exchange
- Nasdaq
- SIC classification
- Services-Health Services (8000)
- Fiscal year end
- 12-31
- CIK
- 0001822359
Filings
- 10-QAug 17, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KMar 16, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Castle BiosciencesCSTL | $344M | −$24.2M |
| Tactile Systems TechnologyTCMD | $330M | $19.1M |
| Fulgent GeneticsFLGT | $323M | −$60.5M |
| DocgoDCGO | $322M | −$196M |
| AngiodynamicsANGO | $320M | −$36.7M |
| CormedixCRMD | $312M | $163M |
| Procept BioroboticsPRCT | $308M | −$95,572 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Docgo — Key figures |url=https://companiesranked.com/en/company/docgo |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Docgo — Key figures. CompaniesRanked. https://companiesranked.com/en/company/docgoBibTeX
@misc{companiesranked-en-company-docgo-2026,
author = {{CompaniesRanked}},
title = {{Docgo — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/docgo}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-018214 · March 16, 2026
{{cite web |title=Docgo — Key figures — 10-K (0001628280-26-018214) |url=https://www.sec.gov/Archives/edgar/data/1822359/000162828026018214/dcgo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-16}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.